
Contents

1	Structural Considerations of the Sclera	1
1.1	Introduction.....	1
1.2	Development of the Sclera.....	1
1.2.1	Prenatal Development: Ultrastructural Studies	1
1.2.2	Prenatal Development: Immunohistochemical Studies	7
1.2.3	Postnatal Development and Age-Related Changes	8
1.3	Anatomy.....	9
1.3.1	Gross and Microscopic Anatomy	9
1.3.2	Ultramicroscopic Anatomy	19
1.4	Biochemistry	22
1.5	Immunohistochemistry	22
1.6	Biomechanics.....	23
1.7	Molecular Structure	23
1.7.1	Collagen.....	23
1.7.2	Elastin	24
1.7.3	Proteoglycans	24
1.7.4	Glycoproteins	25
1.7.5	Matrix-Degrading Enzymes	25
1.7.6	Fibroblast Growth Regulation	26
1.8	Summary	26
	References.....	27
2	Immunologic Considerations of the Sclera	31
2.1	General Immune Response Considerations	32
2.1.1	Components of the Adaptive Immune Response.....	32
2.1.2	Immunoregulation	40
2.1.3	Abnormalities of the Immune Response	41
2.2	Connective Tissue and the Immune Response	45
2.2.1	Fibroblast Functions and the Immune Response.....	45
2.3	The Sclera and the Immune Response: Scleritis.....	46
2.3.1	Immune Characteristics of the Sclera.....	46
2.3.2	The Susceptible Host: Immunogenetics	46

2.3.3	Etiology	47
2.3.4	Pathogenesis	49
2.4	Summary	50
	References.....	51
3	Diagnostic Approach of Episcleritis and Scleritis.....	57
3.1	Investigation of the Illness	58
3.1.1	Major Complaint and History of Present Illness	59
3.1.2	Past History.....	60
3.1.3	Family History.....	60
3.1.4	Past and Present Therapy History.....	60
3.1.5	Review of Systems	60
3.1.6	Systemic Examination.....	62
3.1.7	Ocular Examination.....	64
3.2	Diagnostic Tests	71
3.2.1	Blood Tests	71
3.2.2	Anterior Chamber Polymerase Chain Reaction Testing	79
3.2.3	Smears and Cultures	79
3.2.4	Skin Testing	80
3.2.5	Radiologic Studies.....	80
3.2.6	Anterior Segment Fluorescein Angiography	80
3.2.7	Anterior Segment Indocyanine Green Angiography ...	84
3.2.8	Other Imaging Studies.....	85
3.3	Biopsy	88
3.3.1	Biopsy for Suspected Systemic Vasculitic Disease	88
3.3.2	Biopsy for Suspected Local or Systemic Infectious Disease.....	89
3.4	Data Integration: Diagnosis	89
3.5	Therapeutic Plan	89
3.6	Summary	89
	References.....	90
4	Clinical Considerations of Episcleritis and Scleritis.....	95
4.1	Episcleritis.....	96
4.1.1	Introduction	96
4.1.2	Patient Characteristics	96
4.1.3	Clinical Manifestations.....	97
4.1.4	Classification of Episcleritis	99
4.1.5	Associated Diseases.....	100
4.1.6	Precipitating Factors	100
4.2	Scleritis	102
4.2.1	Introduction	102
4.2.2	Patient Characteristics	102
4.2.3	Clinical Manifestations.....	102
4.2.4	Classification	105

4.2.5	Associated Diseases.....	125
4.2.6	Complications of Scleritis	126
4.3	Summary	132
	References.....	133
5	Pathology in Scleritis	137
5.1	General Considerations of Connective Tissue Inflammation	137
5.1.1	Chronic Nongranulomatous Inflammation	138
5.1.2	Chronic Granulomatous Inflammation	138
5.1.3	Fibrinoid Necrosis	138
5.1.4	Vascular Inflammation.....	139
5.2	Specific Considerations of Scleral Tissue Inflammation	139
5.2.1	Pathology of Episcleritis.....	141
5.2.2	Pathology of Scleritis.....	141
5.3	Biopsy	164
5.3.1	Noninfectious Necrotizing Scleritis	164
5.3.2	Noninfectious Recurrent Diffuse or Nodular (Nonnecrotizing) Scleritis	164
5.3.3	Infectious Scleritis (Diffuse, Nodular, or Necrotizing Scleritis)	165
5.3.4	Biopsy Technique	165
5.4	Summary	166
	References.....	167
6	Noninfectious Scleritis	173
6.1	Systemic Immune-Mediated Disease-Associated Scleritis: Vasculitides	174
6.1.1	Adult Rheumatoid Arthritis.....	174
6.1.2	Systemic Lupus Erythematosus	189
6.1.3	Ankylosing Spondylitis	194
6.1.4	Reactive Arthritis (Reiter)	199
6.1.5	Psoriatic Arthritis	203
6.1.6	Inflammatory Bowel Disease-Associated Arthritis	206
6.1.7	Relapsing Polychondritis.....	208
6.1.8	Polyarteritis Nodosa	211
6.1.9	Allergic Granulomatous Angiitis (Churg–Strauss Syndrome)	213
6.1.10	Granulomatosis with Polyangiitis (Wegener).....	214
6.1.11	Adamantiades–Behçet’s Disease	217
6.1.12	Giant-Cell Arteritis.....	220
6.1.13	Cogan’s Syndrome	222
6.1.14	Systemic Immune-Mediated Diseases Associated with Scleritis: Atopy.....	223
6.1.15	Other Systemic Immune-Mediated Diseases That Rarely May Be Associated with Scleritis and Episcleritis	224
6.1.16	Systemic Immune-Mediated Disease-Associated Scleritis After Ocular Surgery	225

6.2	Dermatological Disease-Associated Scleritis	226
6.2.1	Rosacea.....	226
6.3	Metabolic Disease-Associated Scleritis	226
6.3.1	Gout	226
6.4	Foreign Body Granuloma-Associated Scleritis	227
6.5	Chemical Injury-Associated Scleritis	227
6.6	Summary	228
	References.....	228
7	Infectious Scleritis.....	241
7.1	Bacterial Scleritis.....	242
7.1.1	Gram-Positive Coccus and Gram-Negative Rod Scleritis	242
7.1.2	Mycobacterial Scleritis	245
7.1.3	Spirochetal Scleritis.....	250
7.1.4	Chlamydial Scleritis	254
7.1.5	Actinomycetic Scleritis	254
7.2	Fungal Scleritis	255
7.2.1	Filamentous and Dimorphic Fungal Scleritis	255
7.3	Viral Scleritis	258
7.3.1	Herpes Scleritis.....	258
7.3.2	Mumps Scleritis.....	265
7.4	Parasitic Scleritis.....	265
7.4.1	Protozoal Scleritis.....	266
7.4.2	Helminthic Scleritis	268
7.5	Summary	269
	References.....	270
8	Noninflammatory Diseases of the Sclera.....	277
8.1	Scleral Deposits	277
8.1.1	Scleral Protein Deposition.....	277
8.1.2	Scleral Lipid Deposition.....	281
8.1.3	Scleral Carbohydrate Deposition.....	281
8.1.4	Scleral Mineral Deposition: Calcium	281
8.1.5	Scleral Pigment Deposition: Bilirubin.....	282
8.2	Scleral Thinning (Blue Sclerae).....	283
8.2.1	Scleral Thinning in Inherited or Congenital Diseases	283
8.2.2	Scleral Thinning in Acquired Diseases	286
8.3	Scleral Thickening	287
8.3.1	Nanophthalmos.....	287
8.3.2	Scleropachynsis	287
8.3.3	Phthisis Bulbi.....	287
8.4	Scleral Tumors	288
8.4.1	Dermoid Choristomas.....	288
8.4.2	Epithelial Tumors	288
8.4.3	Dense Connective Tissue Tumors.....	289
8.4.4	Vascular Tumors	289
8.4.5	Blood Cell Tumors	290

8.4.6	Nervous Tumors	290
8.4.7	Pigmented Tumors.....	291
8.4.8	Secondary Tumors	292
8.5	Summary	292
	References.....	292
9	Treatment of Episcleritis and Scleritis	299
9.1	Treatment of Episcleritis	299
9.2	Treatment of Scleritis	300
9.2.1	Medical Treatment.....	300
9.2.2	Ancillary Therapy.....	304
9.2.3	Drug Management Responsibility	304
9.2.4	Surgical Treatment.....	305
9.3	Summary	307
	References.....	307
	Index.....	309

The Sclera

Sainz de la Maza, M.; Tauber, J.; Foster, S.C.

2012, XIII, 320 p., Hardcover

ISBN: 978-1-4419-6501-1